HealthDay News — Increased risk of miscarriage is observed whether women receive selective serotonin reuptake inhibitors during early pregnancy or discontinue their use before pregnancy, according to research published in Obstetrics and Gynecology.

To assess the effect of exposure to selective serotonin reuptake inhibitors (SSRIs) on the risk of miscarriage, Jon Trærup Andersen, MD, PhD, of University Hospital of Copenhagen, and colleagues analyzed data for all registered pregnancies (n=22,884) in Denmark from 1997 to 2010 and their outcomes.

Nearly 13% (12.6%) of women exposed to an SSRI during the first 35 days of pregnancy had a miscarriage, compared with the 11.1% of women who were not exposed to an SSRI. Compared with those who were not exposed, pregnant women exposed to an SSRI had an increased risk of having a miscarriage (adjusted hazard ratio, 1.27; 95% CI: 1.22-1.33).

Continue Reading

Patients who discontinued an SSRI three to 12 months before pregnancy also had an increased risk of having a miscarriage compared with patients who were not exposed (adjusted HR; 1.24; 95% CI: 1.18-1.3).

“Women exposed to SSRIs during early pregnancy were at increased risk of miscarriage as were women discontinuing SSRI treatment before pregnancy, and these risks were similar,” concluded the researchers. “Therefore, treatment with SSRIs during pregnancy should not be discontinued as a result of fear of miscarriage.”


  1. Andersen J et al. Obstetrics and Gynecology. 2014; doi: 10.1097/AOG.0000000000000447